MeVis publishes figures for the first half of fiscal year 2023/2024

EQS-News: MeVis Medical Solutions AG / Key word(s): Half Year Results
MeVis publishes figures for the first half of fiscal year 2023/2024

27.05.2024 / 12:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bremen, May 27, 2024 - MeVis Medical Solutions AG (ISIN: DE000A0LBFE4), a
leading medical imaging software company, today announced its results for
the first half of fiscal year 2023/2024, reporting period October 1, 2023 to
March 31, 2024.

In the first half of the year, the company's revenue amounted to EUR 8,774 k
(previous year: EUR 8,472 k). Of this figure, 27 % (previous year: 26 %) is
attributable to the sale of licenses, 35 % (previous year: 35 %) to
maintenance revenue and 38 % (previous year: 39 %) to other revenue, which
includes services for and recharges to affiliated companies and the parent
company. Earnings before interest and taxes (EBIT) rose from EUR 1,893 k to EUR
2,735 k, which corresponds to an EBIT margin of 24 %, mainly due to the
lower expenses from currency translation compared to the previous year.

Income from loans of financial assets amounted to EUR 643 k (previous year: EUR
624 k) and is attributable to interest income from the loan granted to Varex
Imaging Deutschland AG. This results in earnings before taxes (EBT) of EUR
2,735 k (previous year: EUR 1,893 k).

Income taxes of EUR 74 k (previous year: EUR 64 k) were incurred in the past
half year, therefore, taking into account the expenses from the profit to be
transferred to Varex Imaging Deutschland AG in the amount of EUR 2,661 k
(previous year: EUR 1,829 k), net income for the year amounted to EUR 0 k
(previous year: EUR 0 k).

At this point in time, we are sticking to our forecast: for the 2023/2024
financial year, sales are now expected to increase slightly year-on-year to
between EUR 18.0 m and EUR 18.5 m. In addition to the slight increase in sales
with the customer Hologic, sales in the lung and liver area are also
expected to increase slightly. We expect a slight decline in the area of
development services. For earnings before interest and taxes (EBIT), we
expect stability in the range of EUR 4.5 m to EUR 5.0 m. The forecast slight
growth in sales and the simultaneous increase in personnel costs and other
operating expenses are key drivers for the EBIT outlook.

As in the past reporting period, the Executive Board will regularly review
its expectations in the course of fiscal 2022/2023 on the basis of current
business performance.

Contact:
Kirchhoff, Marcus / CEO


---------------------------------------------------------------------------

27.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        MeVis Medical Solutions AG
                   Caroline-Herschel-Str. 1
                   28359 Bremen
                   Germany
   Phone:          +49 421 224 95 0
   Fax:            +49 421 224 95 999
   E-mail:         ir@mevis.de
   Internet:       http://www.mevis.de
   ISIN:           DE000A0LBFE4
   WKN:            A0LBFE
   Listed:         Regulated Market in Frankfurt (General Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1911777

End of News EQS News Service
---------------------------------------------------------------------------

1911777 27.05.2024 CET/CEST